KX-826 Long-Term Safety Phase 3 For AGA Reached Pr...

文章预览

Suzhou, 20 March, 2025-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that   the long-term safety phase III clinical trial of its in-house developed and potential first-in-class KX-826 tincture for the treatment of AGA has obtained top-line results. Results indicated that the Long-term Safety Clinical Trial has reached its primary endpoint with statistically significant and clinically meaningful outcomes, demonstrating excellent safety and efficacy. The Long-term Safety Clinical Trial is a multi-center, open-label study designed to evaluate the long-term safety of the topical use of KX-826 for the treatment of AGA patients in China (treatment period of 52 weeks). The Long-term Safety Clinical Trial involves a total of 16 clinical research centers in China, with Professor Jianzhong Zhang ( 張建中 ) from Peking University People’s Hospital as the lead principal investigator. The primary endpoint of the trial is the incidence of treatment-emergent adver ………………………………